**Effectiveness of HB2 (anti-CD7) – saporin immunotoxin in an *in vivo* model of human T-cell leukaemia developed in severe combined immunodeficient mice**

B.J. Morland¹, J. Barley², D. Boehm¹, S.U. Flavell¹, N. Ghaleb¹, J.A. Kohler¹, K. Okayama¹, B. Wilkins² & D.J. Flavell¹

¹Simon Flavell Leukaemia Research Laboratory; ²Department of Pathology and ³Department of Child Health, Southampton General Hospital, UK.

**Summary** The transplantation of the human T-cell acute lymphoblastic leukaemia (T-ALL) cell line HS2-2 into severe combined immunodeficient (SCID) mice was found to produce a disseminated pattern of leukaemia similar to that seen in man. The intravenous injection of 10⁷ HS2-2 cells was associated with a universally fatal leukaemia. Histopathological examination of animals revealed the spread of leukaemia initially from bone marrow to involve all major organs including the meninges. An immunotoxin (HB2-Sap) was constructed by conjugating the anti-CD7 MAbs HB2 to the ribosome-inactivating protein saporin. An *in vitro* protein synthesis inhibition assay revealed specific delivery of HB2-Sap immunotoxin (IT) to CD7⁺ HS2-2 target cells with an IC₅₀ of 4.5 pm. When SCID mice were injected with 10⁷ HS2-2 cells and then treated 8 days later with a single intravenous dose of 10 μg of immunotoxin there was a significant therapeutic effect evidenced by the numbers of animals surviving in the therapy group compared with untreated controls ($\chi^2 = 5.348, P = 0.021$). These results demonstrate the useful application of human leukaemia xenografts in SCID mice and the potential therapeutic effect of an anti-CD7 immunotoxin in human T-ALL.

The ability to manipulate an accurate model of human cancer in an animal host is one way in which developments in the understanding of tumour origins, progression and treatment can be advanced. To this end much work has focused on human tumour xenografts grown in nude mice (Fogh et al., 1977; Giovanella et al., 1978). Similarly, the nude mouse has been extensively utilised to study human leukaemia (Watanabe et al., 1978, 1980), but because the resultant tumour growth manifests itself either as a solid mass or as malignant ascites this model bears little resemblance to the spectrum of disease seen in man.

The SCID mouse was first described by Bosma et al. (1983), who reported its potential for the transplantation of allogeneic haematopoietic cells from Balb/c animals into these animals. Following this study other workers have reported the ability to engraft human lymphoid cells and stem cells to produce normal human lymphoid and myeloid differentiation in these mice (Kamel-Reid & Dick, 1988; McCune et al., 1988; Mosier et al., 1988; Mosier, 1990). This has in turn generated interest in the study of a murine model of AIDS using HIV-1-infected human haematopoietic cells (Namikawa et al., 1988; McCune et al., 1990). The first report of a human leukaemia cell line xenograft into SCID mice was by Kamel-Reid et al. (1989), resulting in disseminated growth of a pre-B acute leukaemia cell line. Subsequently a range of human leukaemias of T-cell and non-T-cell origin have been demonstrated to display similar disseminated growth patterns mimicking much more closely than previous animal models the clinical picture of human leukaemia (Ghetie et al., 1990; Cesano et al., 1991; Kamel-Reid et al., 1991; Jansen et al., 1992a; Uckun et al., 1992a). Other tumour types including Epstein–Barr virus-associated lymphoproliferative disease (Cannon et al., 1990; Partillo et al., 1991; Rowe et al., 1991), T-cell lymphoma (Charley et al., 1990; Waller et al., 1991) and lung and other solid carcinomas (Reddy et al., 1987) have also been successfully engrafted into SCID mice.

In this report we describe the picture of disseminated human acute T-cell leukaemia which develops following intravenous injection of cells from the CD7⁺ T-ALL cell line HS2-2 into SCID mice. We describe the histological and immunohistochemical findings in tissue sections obtained from these animals. This murine model was then used to explore the *in vivo* therapeutic efficacy of an immunotoxin constructed with the anti-CD7 monoclonal antibody HB2 conjugated to the ribosome-inactivating protein (RIP) saporin derived from the soapwort plant *Saponaria officinalis*.

**Materials and methods**

*Human acute T-cell leukaemia cell line*

The CD7⁺ T-ALL cell line HS2-2 (Adams et al., 1970) was maintained in RPMI-1640 medium containing 10% fetal calf serum (Gibco) and supplemented with 1 mmol of glutamine and 1 mmol of sodium pyruvate. Cells were maintained in the logarithmic phase of growth by passage at regular intervals.

*Animals*

SCID mice (8–10 weeks of age) were obtained from the breeding colony housed in the Biomedical Research Facility at Southampton General Hospital. Animals were housed under sterile conditions in an isolator unit and fed on autoclaved food and filter-sterilised water. Animals for experimental use were transferred from the isolator unit to microisolator filter top cages for ease of handling during experimental procedures. All experimental interventions were performed within the confines of a laminar flow hood under aseptic conditions.

*T-cell leukaemia inoculation*

HS2-2 cells were washed in RPMI and viability checked using trypan blue dye exclusion. Cells were resuspended in RPMI to a concentration whereby each animal received the same volume of inoculum (0.3 ml). Mice were injected intravenously into the lateral tail vein. Recipient animals were observed closely for signs of illness or distress (ruffled fur, weight loss, tachypnoea) and were killed in the terminal phase of their illness unless dying spontaneously.
Pathology
An autopsy was performed on each animal and the macroscopic findings recorded. The following tissues were removed for histological examination and fixed in 10% buffered formalin solution: liver, kidneys, lungs, heart, spleen, brain and both femurs (for bone marrow examination). Femurs were subsequently decalcified and all tissues were embedded in paraffin wax prior to sectioning and mounting.

Histology
Tissue sections were routinely stained with haematoxylin and eosin. Immunocytochemical staining was also performed on freshly cut tissue sections. A polyclonal anti-human CD3 (Dako) antibody was used to demonstrate human T-cell infiltration within decalcified femur sections and the anti-human CD43 monoclonal antibodies MT1 and DFT1 were used on the other tissue sections. A standard avidin–biotin–complex (ABC) peroxidase method for immunohistochemical staining was used and slides were counterstained with haematoxylin.

Preparation of the anti-T-cell immunotoxin HB2–Sap
Monoclonal anti-CD7 antibody HB2 was obtained by injecting 1 x 10^7 hybridoma cells into the peritoneal cavity of pristane-primed Balb/c mice. The 75 lgG fraction of ascitic fluid was isolated by precipitation with 6 M ammonium sulphate followed by ion-exchange chromatography on DEAE–Sephrose and a further gel filtration step on Sephacryl S200 HR (Pharmacia). The single-chain ribosome-inactivating protein (RIP) saporin was purified from the seeds of Saponaria officinalis as described previously (Stirpe et al., 1983). The conjugation of saporin to the CD7 monoclonal antibody was performed as previously described (Thorpe et al., 1985). Briefly, both the monoclonal antibody HB2 and saporin were reacted with N-succinimidyl-3-(2-pyridyl-dithio)propionate (SPDP) (Pharmacia) to yield 2-pyridyl disulphide-substituted products. The 2-pyridyl disulphide-substituted saporin was reduced with 50 mM dithiothreitol and the reduced product reacted for 24 h at room temperature with the substituted HB2 antibody. Immunoconjugate was separated from unreacted free saporin by gel filtration on Sephacryl S200 HR. Free unconjugated HB2 antibody was removed by cation-exchange chromatography on CM-Sephrose. The purity of the final immunotoxin product was confirmed by SDS–PAGE.

Cytotoxicity of immunotoxin in vitro
In vitro cytotoxicity of the HB2–Sap immunotoxin was assessed in a [3H]leucine incorporation assay that we have described previously (Flavell et al., 1991). Triplicate cultures of HSB-2 cells at a density of 1 x 10^3 cells per well in 96-well microculture plates were exposed for 48 h at 37°C to immunotoxin or equimolar concentrations of saporin and HB2 antibody at each experimental concentration. Cells were then pulsed for 12 h with 1.0 µCi of [3H]leucine (TRK 510, Amersham International, UK) and finally harvested onto glass fibre filters using a Skatron cell harvester. The amount of radioactive leucine uptake by cells was measured by scintillation counting using a Packard scintillation counter. Results obtained for experimental cultures are expressed as a percentage of the amount of [3H]leucine incorporation observed in untreated control cultures.

Establishment of human T-ALL in SCID mice
In an initial experiment eight SCID mice were inoculated with 10^7 HSB-2 cells intravenously. Five animals were pretreated with total body irradiation (4 Gy) immediately prior to inoculation of cells, and three animals received no irradiation. Disease spread and progression was monitored as described above. Findings described later revealed that total body irradiation was unnecessary for successful engraftment and therefore in all subsequent experiments animals were not treated with total body irradiation.

Establishing disease progression in SCID mice
In order to monitor the progression of human T-ALL in SCID mice, 35 animals were injected intravenously with 10^7 HSB-2 cells. Initially three animals were sacrificed on a weekly basis and full post-mortem examinations and histological examinations documented. By 6 weeks all animals had developed leukaemia and had been sacrificed or had died naturally.

Challenge with graded numbers of HSB-2 cells
In an attempt to establish a suitable working model for in vivo immunotoxin experiments, 40 animals were injected intravenously with varying numbers of HSB-2 cells ranging from 10^4 to 10^7 cells per animal. Animals were monitored until showing signs of disease or until dying naturally. Survival curves were established for each group of animals.

Immunotoxin study with T-ALL in SCID mice
Groups of animals were initially injected intravenously with 10^7 HSB-2 cells. Seven days later the mice were given a single 10 µg intravenous dose of HB2–Sap immunotoxin (IT) (equivalent to approximately 0.5 mg kg^-1) administered in a 200 µl volume of PBS. Control animals were either sham treated with phosphate-buffered saline (PBS) (200 µl) or treated with the monoclonal HB2 antibody also at 10 µg per animal (in 200 µl volume) or with 10 µg of a non-targeting isotype, linker, toxin-matched anti-CD19–saporin immunotoxin control (BU12–Sap). Similarly, experimental animals which had not received the HSB-2 leukaemic cells were treated with immunotoxin, PBS or monoclonal antibody. Survival curves were plotted and analysed.

Results
The characteristics of human T-ALL in SCID mice
The initial pilot experiment demonstrated that irrespective of pretreatment with total body irradiation all of the animals that had been injected with 10^7 HSB-2 cells developed disseminated HSB-2 leukaemia. Clinical examination of the animals revealed that in the terminal stages of disease they developed weight loss, tachypnoea and ruffling of the fur. In addition a few animals appeared to have paralysis of the hind limbs, thought to be due to infiltration of the CNS with leukaemia. Gross examination of organs at the time of autopsy demonstrated several abnormalities. The majority of animals had obvious infiltration of the liver with discrete areas of solid white tissue replacing normal liver tissue. Renal involvement was characterised by multiple nodules of tumour on the renal capsule, which on occasion infiltrated deeply into the substance of the kidney itself. Solid white infiltrates were often seen within the lung parenchyma, and pericardial deposits were obvious in at least two animals. There was no obvious lymph node enlargement in any of the animals, although one mouse had a large mediastinal tumour similar in character to the mediastinal enlargement seen in some patients with T-cell lymphomas and leukaemias. The spleens were small and demonstrated no obvious leukaemic infiltration. The brains similarly showed no macroscopic abnormality even in the presence of neurological symptoms.

Histological examination of tissue demonstrated several abnormalities listed below. Femur secretions revealed that the bone marrow morphology in diseased animals consisted of a mononuclear cell infiltrate replacing all of the normal haematological cells and ablating marrow spaces. The liver showed disseminated disease throughout the normal parenchyma. Kidney involvement was apparent as either capsular...
nodules or perivascular infiltration, a pattern that was similar to that seen in lung. The spleen was apparently uninvolved. Sections of brain demonstrated a meningeal infiltration of leukaemic cells with a similar pattern to the CNS infiltration seen in humans with leukaemia.

Immunohistochemical staining of tissues demonstrated the leukaemic infiltration of organs more accurately while also confirming that infiltrating cells were indeed human. Normal SCID mouse tissues demonstrated no cross-reactivity with the antibodies used. The polyclonal CD3 antibody was used on femur sections and confirmed the cellular infiltrate to be human T cell in origin (Figure 1a and b). Likewise, the other organ tissue sections, when stained using the CD43 antibodies, confirmed that the leukaemic infiltrates seen in the H&E sections documented above were indeed human T-ALL in origin (Figure 1c–f).

The results from those animals that were serially sacrificed to monitor the progress of disease are shown in Figure 2. Bone marrow infiltration was the first event to occur and could be detected as early as 7 days from the time of the initial inoculation. With the passage of time there was a progressive dissemination of the leukaemic cells such that at the stage when all the animals were dying at 6 weeks they all had multiorgan involvement. Leukaemia was universally seen

Figure 1 Histopathology of HSB-2 human T-ALL in SCID mice. a, Photomicrograph of femur section demonstrating the diffuse monomorphic leukaemic infiltrate staining positive with anti-human CD3 polyclonal antibody. Immunoperoxidase \( \times 125 \). b, High-power view of bone marrow leukaemic infiltrate showing strong reactivity to anti-CD3 antibody. Immunoperoxidase \( \times 200 \). c, Immunohistochemical staining of liver with anti-CD43 antibody showing diffuse leukaemic deposits within the normal parenchyma. Immunoperoxidase \( \times 125 \). d, Replacement of normal renal architecture with heavy CD43-positive leukaemic infiltrate. Immunoperoxidase \( \times 62 \). e, Strong CD43 expression in a leukaemic infiltrate surrounding a pulmonary vessel. Immunoperoxidase \( \times 125 \). f, Immunohistochemical staining (CD43) of a meningeal leukaemic deposit overlying the cerebral cortex. Immunoperoxidase \( \times 125 \).
in all animals given an i.v. inoculum of 10⁷ HSB-2 cells.

The result of administering graded numbers of HSB-2 cells to SCID mice is shown in Figure 3. There is a clear dose effect seen, with all animals given the highest cell inoculum (10⁷) dying by 52 days (mean survival 43 days), while in animals given 10⁶ cells per animal only one death occurred by 150 days.

In vitro cytotoxicity of HSB-2-Sap immunotoxin

Triplicate cultures of 1 × 10⁷ HSB-2 cells were exposed for 48 h to increasing concentrations of HB2-Sap immunotoxin (10⁻¹² to 10⁻⁷ M). Identical cultures were set up with equimolar mixtures of saporin and HB2 antibody and with HB2 antibody alone. Cultures of untreated controls were set up with medium alone. After 48 h of exposure [³H]leucine uptake was evaluated in all cell cultures and results expressed as a percentage of the control levels, as shown in Figure 4. An IC₅₀ of 4.5 pm was obtained for the HB2-Sap immunotoxin, whereas the IC₅₀ for the equimolar concentration of saporin and HB2 antibody was 0.14 μM, representing a 31,000-fold increase in toxicity. The native HB2 antibody at all concentrations had no effect on HSB-2 cells.

Two experiments were performed in which the CD7-specific delivery of HB2-Sap immunotoxin was demonstrated. In a similar group of experiments to those described above the immunotoxin HB2-Sap was added to cultures of the CD7⁺ cell line HL60 in concentrations varying from 10⁻¹² to 10⁻⁷ M. Cells were also exposed to saporin in the same molar concentrations and to control medium only. Exposure was for 48 h and [³H]leucine uptake was performed and analysed as described above. The immunotoxin demonstrably failed to deliver an effective dose of saporin to HL60 cells (IC₅₀ for HB2-Sap 0.025 μM vs 0.043 μM for saporin alone) (Figure 5).

In a second specificity experiment an attempt was made to block the binding of the HB2-Sap immunotoxin to HSB-2 cells by incubating in the presence of increasing concentrations of the native anti-CD7 antibody HB2. HSB-2 cells were exposed for 48 h to a fixed concentration of HB2-Sap immunotoxin (10⁻⁹ M) in the presence of increasing concentrations of HB2 antibody (10⁻¹ to 10⁻¹ M), then [³H]leucine incorporation was determined. The resulting dose-response curve demonstrated that in the presence of 10⁻⁷ M HB2 the cytotoxic effect of the immunotoxin was almost completely abrogated (Figure 6).

![Figure 2](image2.png)

Figure 2 Progression of disease in SCID mice injected with 10⁷ HSB-2 cells. The proportion of animals with histological evidence of HSB-2 infiltration of various organs is shown in relation to the age of the animal at the time of death.

![Figure 3](image3.png)

Figure 3 The effect of giving graded doses of HSB-2 cells by intravenous injection into SCID mice. Results are expressed as the percentage of surviving animals with time in mice receiving (○-○) 10⁷ cells, (▼-▼) 10⁶ cells, (△-△) 10⁵ cells and (□-□) 10⁴ cells per animal. Control animals (▪-▪) received PBS alone.

![Figure 4](image4.png)

Figure 4 Protein synthesis levels in HSB-2 cells exposed to various concentrations of HB2-Sap immunotoxin (▼-▼) (IC₅₀ 4.5 pmol), an equimolar solution of free saporin and HB2 MAb (■-■) (IC₅₀ 0.14 μmol) and HB2 MAb alone (△-△) (s.d. <5% for all points).

![Figure 5](image5.png)

Figure 5 Protein synthesis levels in the CD7⁺ cell line HL60 exposed to various concentrations of HB2-Sap immunotoxin (▼-▼), an equimolar solution of free saporin and HB2 MAb (■-■) and HB2 MAb alone (△-△) (s.d. <5% for all points).
We constructed an immunotoxin with the plant toxin ricin and the anti-CD7 monoclonal antibody (Vallera et al., 1983; Myers et al., 1984; Fishwild et al., 1992), and with the single-chain ribosome-inactivating protein pokeweed antiviral protein (PAP) (Ramakrishnan & Houston, 1984). The immunotoxin described by Ramakrishnan and Houston (1984) was constructed with the anti-CD7 monoclonal antibody 3A1 and PAP, and when directed against HSB-2 cells in vitro gave an IC_{50} of 0.11 nM. Our immunotoxin HB2-Sap gave an IC_{50} of 4.5 pm, similar to the figure (6.7 pm) reported by Fishwild et al. (1992).

Interpretation of cytotoxicity between different immunotoxins needs to be examined with caution however. There are a number of possible reasons as to why our anti-CD7–saporin IT HB2–Sap appears more potent than some of the other published anti-CD7 ITs constructed with different toxins. Firstly, it may be that the HSB-2 target cells used in our studies may be intrinsically more sensitive to the action of immunotoxins generally. Only by comparing all the other ITs directly with each other against the same target cell line can this issue be resolved. Also, antibody affinity and the locality of the epitope recognised by the antibody in the target molecule can have marked effects in immunotoxin potency (Youle & Neville, 1982), and equally these considerations may be responsible for the observed differences in potency.

In previous studies in our laboratory utilising a bispecific antibody, one Fab arm of which was constructed with the same anti-CD7 antibody HB2 and the other Fab arm with an anti-saporin antibody (HB2 × DB7–18), the delivery of saporin to HSB-2 cells was less efficient with an achieved IC_{50} of 0.23 nM (expressed as the concentration of free saporin in

**Discussion**

Our study has demonstrated that the intravenous administration of the human T-ALL cell line HSB-2 into SCID mice produces a disseminated pattern of disease that closely mimics the pattern of disease observed in humans with acute lymphoblastic leukaemia. We were able to show that the anti-CD7–saporin immunotoxin HB2–Sap exerted a selective and potent cytotoxic effect against CD7^+ HSB-2 cells in vitro and that this also translated into a significant in vivo therapeutic effect in HSB-2-bearing SCID mice. Thus, there was a prolonged survival of HSB-2-bearing animals given a single 10 μg i.v. dose of HB2-Sap IT.

The observation that human acute leukaemia cells can be engrafted into SCID mice to produce a pattern of disease with biological similarities to human leukaemia is an important advance in our ability to be able to observe and manipulate in vitro therapeutic interventions. In nude mouse experimental models of human leukaemia, localised growth of solid tumours occurs (Dillman et al., 1985) and only a limited degree of extrapolation is possible to the disseminated pattern of disease seen in humans. The nude mouse is therefore limited to the information it can provide with respect to the biology and therapy of human leukaemia. The hope is that the SCID mouse model will provide a tool to aid the closer understanding of the complex in vivo interactions involved in disease states such as this.

One potential role for the SCID mouse model of leukaemia is in the assessment of novel therapeutic approaches such as the use of targeted immunotherapy. In a previous study (Flavell et al., 1991) we showed that the ribosome-inactivating protein saporin has potent in vitro cytotoxicity when targeted with a bispecific antibody to the CD7 surface antigen of HSB-2 cells. In the present study we have clearly demonstrated the effective and selective in vitro cytotoxicity of an immunotoxin constructed with the anti-CD7 monoclonal antibody HB2 and saporin. Other workers have described the potency of immunotoxins constructed with the plant toxin ricin and anti-CD7 monoclonal antibodies (Vallera et al., 1983; Myers et al., 1984; Fishwild et al., 1992), and with the single-chain ribosome-inactivating protein pokeweed antiviral protein (PAP) (Ramakrishnan & Houston, 1984). The immunotoxin described by Ramakrishnan and Houston (1984) was constructed with the anti-CD7 monoclonal antibody 3A1 and PAP, and when directed against HSB-2 cells in vitro gave an IC_{50} of 0.11 nM. Our immunotoxin HB2-Sap gave an IC_{50} of 4.5 pm, similar to the figure (6.7 pm) reported by Fishwild et al. (1992).

Interpretation of cytotoxicity between different immunotoxins needs to be examined with caution however. There are a number of possible reasons as to why our anti-CD7–saporin IT HB2–Sap appears more potent than some of the other published anti-CD7 ITs constructed with different toxins. Firstly, it may be that the HSB-2 target cells used in our studies may be intrinsically more sensitive to the action of immunotoxins generally. Only by comparing all the other ITs directly with each other against the same target cell line can this issue be resolved. Also, antibody affinity and the locality of the epitope recognised by the antibody in the target molecule can have marked effects in immunotoxin potency (Youle & Neville, 1982), and equally these considerations may be responsible for the observed differences in potency.

In previous studies in our laboratory utilising a bispecific antibody, one Fab arm of which was constructed with the same anti-CD7 antibody HB2 and the other Fab arm with an anti-saporin antibody (HB2 × DB7–18), the delivery of saporin to HSB-2 cells was less efficient with an achieved IC_{50} of 0.23 nM (expressed as the concentration of free saporin in
The highly selective and highly cytotoxic nature of immunotoxins makes them ideal potential candidates for improving the therapy of haematological malignancies such as acute leukaemias and lymphomas. To date, however, only a limited number of clinical data have been collected in the systemic application of immunotoxins in this field. The use of immunotoxins in purging the bone marrow of autologous transplantation patients with ALL has been extensively investigated and is quite widely used in clinical practice (Uckun et al., 1990). The clinical systemic use of immunotoxins in haematological malignancy is much less well researched and centres around preliminary phase I data (Laurent et al., 1986; Vitetta et al., 1991; Grossbard et al., 1992; Uckun et al., 1992b). Little useful clinical information on the likely efficacy of such treatment in humans therefore currently exists but is slowly accumulating. Future phase II and III trials will be necessary in order to determine the precise role, if any, of immunotoxins may have in the advancement of therapy in haematological malignancy.

In conclusion therefore we have been able to demonstrate the widespread dissemination of human T-ALL in SCID mice producing a pattern of disease mimicking the natural history of acute lymphoblastic leukaemia in man. Such a model may have many potential uses in the investigation of therapeutic and pharmacokinetic studies and the research of new immunotoxin agents. Using this animal model we have been able to show a significant therapeutic effect from a single intravenous injection of a CD7/saporin immunotoxin. Our results support the hopes that such agents may play a useful future role in the clinical management of patients with T-ALL.

We would like to acknowledge the help given by Julie Williams and Penny Johnson from the Immunohistochemistry Laboratory in the Department of Pathology, Southampton General Hospital, for their help in preparation of histological material.

This work was supported by The Cancer Research Campaign.

References

ADAMS, R.A., POTHIER, L., FLOWERS, A., LAZARUS, H., FARBER, S. & FOLEY, G.E. (1970). The question of stemlines in human acute leukaemia. Exp. Cell Res., 62, 5–10.

BOSMA, G.C., CUSTER, R.P. & BOSMA, M.J. (1983). A severe combined immunodeficiency in the mouse. Nature, 301, 527–530.

CANNON, M.J., PISA, P., FOX, R.I. & COOPER, R.I. (1990). Epstein–Barr virus induces aggressive lymphoproliferative disorders of human B cell origin. In SCID/hu chimeric mice. J. Clin. Invest., 85, 1333–1337.

CESANGO, A., O’CONNOR, R., LANGE, B., FINAN, J., ROVERA, G. & SANTOLI, D. (1991). Homing and progression patterns of childhood acute lymphoblastic leukaemia in severe combined immunodeficient mice. Blood, 77, 2463–2474.

CHARLEY, M.R., THARP, M., LOCKER, J., DENG, J.-S., GOLSEN, J.B., MAURON, T., DICK, P., ABELL, E. & JEGASOTHY, B. (1990). Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID mice. J. Invest. Dermatol., 94, 381–384.

DILLMAN, R.O., JOHNSON, D.E., SHAWLER, D.L., HALPERN, S.E., LEONARD, J.E. & HAGAN, P.L. (1985). Athymic mouse model of a human T-cell tumour. Cancer Res., 45, 5632–5636.

DORSCHKIND, K., POLLACK, S.B., BOSMA, M.J. & PHILLIPS, R.A. (1985). Natural killer cells are present in mice with severe combined immunodeficiency. J. Immunol., 134, 3798–3801.

FITWELL, D.M., ABERLE, S., BERNHARD, S.L. & KUNG, A.H.C. (1992). Efficacy of an anti-CD7–ricin A-chain immunoonconjugate in a novel murine model of human T-cell leukaemia. Cancer Res., 52, 3056–3062.

FLAVELL, D.J., COOPER, S., MORLAND, B. & FLAVELL, S.U. (1991). Characteristics and performance of a bispecific Fab(α′) antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line. Br. J. Cancer, 64, 274–280.

FOGH, J., FOGH, J.M. & ORFEO, T. (1977). One hundred and twenty-seven cultured human cell lines producing tumours in nude mice. J. Natl Cancer Inst., 59, 221–226.

GHETIE, M.A., TUCKER, T., JONES, D., UHR, J.W. & VITETTA, E.S. (1990). Disseminated or localised growth of a human B-cell tumour (Daudi) in SCID mice. Int. J. Cancer, 45, 481–485.

GIOVANELLA, B.C., STEHLIN, J.R., WALLIS, J., LEE, S.S. & SHEPHARD, R.C. (1978). Heterotransplantation of human cancers into nude mice. A model system for human cancer chemotherapy. Cancer, 42, 2269–2281.

GROSSBARD, M.L., FREEDMAN, A.S., RITZ, J., CORAL, F., GOLD-MACHER, V.S., ELISEO, L., SPECTOR, N., DEAR, K., LAMBERT, J.M., BLATTLER, W.A., EPSTEIN, C.L. & NADLER, L.M. (1992). Serothery of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood, 79, 576–585.

JANSEN, B., UCKUN, F.M., JASZCZ, W.B. & KERSEY, J.H. (1992a). Establishment of a human t(4:11) leukemia in SCID mice and successful treatment using anti CD19 (B4)- pokeweed antiviral protein immunotoxin. Cancer Res., 52, 406–412.

JANSEN, B., VALLERA, D.A., JASZCZ, W.B., NGUYEN, D. & KERSEY, J.H. (1992b). Successful treatment of human acute T-cell leukaemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res., 52, 1314–1321.

KAMEL-REID, S. & DICK, J.E. (1988). Engraftment of immune-deficient mice with human haematopoietic stem cells. Science, 242, 1706–1709.

KAMEL-REID, S., LETARTE, M., SIRARD, C., DOEDENS, M., GRUNBERGER, T., FULOP, G., FREEDMAN, M.H., PHILLIPS, R.A. & DICK, J.E. (1989). A model of human acute lymphoblastic leukemia in immune deficient SCID mice. Science, 246, 1597–1600.

KAMEL-REID, S., LETARTE, M., DOEDENS, M., GREAVES, A., MURDOCH, B., GRUNBERGER, T., LAPIDOT, T., THORNER, P., FREEDMAN, M.H., PHILLIPS, R.A. & DICK, J.E. (1991). Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood, 78, 2973–2981.
THORPE, P.E., BROWN, A.N.F., BREMNER, Jr, J.A.G., FOXWELL, B.M.J. & STIRPE, F. (1985). An immunotoxin composed of monoclonal anti-Th1 antibody and a ribosome inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J. Natl Cancer Inst., 75, 151–159.